Recombinant collagen nasal spray and method of making same
By optimizing the formula of the recombinant collagen nasal spray, the problems of unstable efficacy and mucosal irritation in the treatment of allergic rhinitis of existing nasal sprays have been solved. The synergistic effect of nasal mucosal repair and preservatives has been achieved, extending the product's shelf life.
Patent Information
- Application Number
- CN202610731500.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-26
- Publication Date
- 2026-07-17
AI Technical Summary
Existing nasal sprays have unstable efficacy in treating allergic rhinitis, and long-term use can easily cause irritation and damage to the nasal mucosa. Furthermore, the physicochemical properties of nasal irrigation solutions are not compatible and can aggravate mucosal inflammation.
This nasal spray uses recombinant collagen and contains ingredients such as trehalose, glycerin, sodium hyaluronate, recombinant type III collagen, p-hydroxyacetophenone, chlorphenesin, and 1,2-hexanediol. It adjusts the pH and osmotic pressure to create a suitable environment for the nasal cavity, promotes mucosal repair, and uses mild preservatives to extend its shelf life.
The recombinant collagen nasal spray, through its optimized formula, promotes the restoration of the nasal mucosal barrier function, reduces damage from external stimuli, and extends the shelf life after opening with mild preservatives, making it suitable for use in the human nasal cavity.
Smart Images
Figure CN122398728A_ABST
Abstract
Citation Information
Patent Citations
Recombinant humanized collagen and its preparation method
CN102443057A
A sterile nasal spray containing glucocorticoids and its preparation method
CN108403638B
A lyophilized hyaluronic acid formulation for nasal spray, its preparation method and application
CN111265590B